Identification of the frequency and characteristics of bulky versus non-bulky lymphomatous disease in chronic lymphocytic leukaemia (CLL)

Research output: Contribution to journalMeeting Abstractpeer-review

Abstract

Multiple markers are used in the prognostication of CLL, most important being the immunoglobulin hyper-variable region (IGHV) mutational status and cytogenetics. However, there may be predictive value for some new agents (venetoclax) as well as chemo-immunotherapy regimens in the presence or
absence of bulky lymphadenopathy (Roberts, 2019). There is no clear definition for “bulky disease”in the literature. Some groups define it as the presence of any lymph node 350 mm as determined by radiological scans or clinical examination. Although there has been documented association between bulky disease and del(11q), this is not a consistent finding (Dohner. Blood. 1997; Joshi. Can Gen. 2007; Jain. Blood. 2012). The purpose of this study was to assess the impact of bulky disease on patient outcome and to reassess cytogenetic and other relationships.
Original languageEnglish
Pages (from-to)207-209
Number of pages3
JournalLeukemia and Lymphoma
Volume61
Issue numberS1
DOIs
Publication statusPublished - 21 May 2020
EventXVIII International Workshop on Chronic Lymphocytic Leukemia - EICC: Edinburgh International Conference Centre, Edinburgh, United Kingdom
Duration: 20 Sep 201923 Sep 2019
https://www.iwcll2019.org/ (Conference website)

Keywords

  • bulky lymphomatous disease
  • non-bulky lymphomatous disease
  • chronic lymphocytic leukaemia
  • prognostication
  • IGHV
  • mutational status
  • Cytogenetics
  • venetoclax
  • chemo-immunotherapy

Fingerprint

Dive into the research topics of 'Identification of the frequency and characteristics of bulky versus non-bulky lymphomatous disease in chronic lymphocytic leukaemia (CLL)'. Together they form a unique fingerprint.

Cite this